Rhea Sibal

Ms. Rhea Sibal


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
RSRhea Sibal
Rhea Sibal
GBG Balamurugan
G Balamurugan
JLJasmine Langley
Jasmine Langley
YGYitka Graham
Yitka Graham
KMKamal Mahawar
Kamal Mahawar
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes due to their efficacy in reducing appetite and body weight. However, by inducing caloric restriction and altering gastrointestinal physiology, GLP-1RAs may predispose patients to nutritional deficiencies. This review aimed to synthesise current evidence on energy, protein, vitamin, and mineral status in GLP-1RA users, and contextualises these findings with metabolic and bariatric surgery (MBS) guidelines. While metabolic and bariatric surgery (MBS) guidelines mandate structured nutritional monitoring, no equivalent frameworks exist for GLP-1RA therapy, highlighting a critical gap that justifies the need for this review. Methods: A narrative review was conducted in three stages: (i) searching PubMed and Embase OVID (August 2025) using MeSH terms and free-text keywords related to GLP-1RAs, micronutrients, and obesity; (ii) screening abstracts and full texts for eligibility; and (iii) synthesising results with comparison to bariatric surgery protocols. Eligible studies included clinical trials, observational cohorts, and reviews reporting nutritional outcomes in GLP-1RA users or describing MBS monitoring guidelines. Results: GLP-1RA therapy consistently reduced caloric intake, with frequent inadequacy of protein intake and occasional sarcopenia. Observational data reported that users developed nutritional deficiencies within 12 months, most commonly vitamin D, followed by thiamine and other B vitamins. Mineral deficiencies, particularly in iron, calcium, magnesium, and potassium, were also observed. Conclusions: GLP-1RAs are associated with clinically relevant risks of protein, vitamin, and mineral deficiencies. The absence of formal monitoring protocols represents an unmet clinical need, and adaptation of surveillance, as seen in MBS, which may help mitigate long-term complications.

23 July 2025 in BMJ
Verified
Journal Article
Closed access
RSRhea Sibal
Rhea Sibal
GWGeorge Webster
George Webster
EMElgan Manton-Roseblade
Elgan Manton-Roseblade

4 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
RSRhea Sibal
Rhea Sibal
GBG Balamurugan
G Balamurugan
MAMohammed Aradaib
Mohammed Aradaib
YGYitka Graham
Yitka Graham
KMKamal Mahawar
Kamal Mahawar
Intragastric balloons (IGBs) were developed to bridge the gap between lifestyle intervention and Metabolic and Bariatric Surgery (MBS), but the advent of highly efficacious pharmacotherapies and Endoscopic Sleeve Gastroplasty (ESG) has challenged their role. This narrative review synthesises contemporary evidence and guideline recommendations regarding IGBs, focusing on short-term efficacy, durability, safety, psychological aspects, and health system considerations in comparison with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), dual GIP (Glucose-dependent Insulinotropic Polypeptide)/GLP-1 RAs, ESG, and MBS. Across randomised trials and meta-analyses, IGBs consistently produce modest short-term weight loss of approximately 10–15% total body weight at six months, with frequent weight regain following removal and limited long-term benefit. In contrast, modern pharmacotherapy achieves greater and more durable weight loss with fewer procedural risks. Current guidelines therefore position IGBs as adjunctive or bridging interventions reserved for selected patient subgroups, rather than as a dominant intermediate therapy. Overall, current evidence supports a selective role for IGBs as bridging, adjunctive, or combination interventions within multimodal obesity pathways, particularly for patients who cannot access or tolerate pharmacotherapy or who require a behavioural and metabolic bridge to surgery.